Data Insights

Filter search results

By Themes
Showing 20 results out of 20834
Features

Breaking barriers – the potential of subcutaneous drug delivery

Cancer rates are rising sharply just as healthcare providers are being asked to implement enormous efficiency savings, making innovation crucial to the future of cancer care. Elly Earls met Halozyme's Kurt Gustafson and Roche Products' Julian Cole, to find out how a revolutionary new subcutaneous drug delivery platform called ENHANZE™ could be part of the solution.

Features

Tumour-targeting ADCs: delivering the anti-cancer warhead

Antibody-drug conjugates combine the efficacy of cytotoxic drugs and the tumour-specific targeting of antibodies to maximise anti-cancer potency and minimise side effects. Chris Lo talks to experts in the field of ADC development to discover the potential of this burgeoning treatment type, and the challenges involved in getting it right.